相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease
Wei Li et al.
HEMATOLOGICAL ONCOLOGY (2022)
Multiple Myeloma, Version 3.2022 Featured Updates to the NCCN Guidelines
Natalie S. Callander et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma
Anthony D. Nehlsen et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy
Sung-Soo Park et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
Yimei Que et al.
FRONTIERS IN IMMUNOLOGY (2021)
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome (vol 105, pg 201, 2020)
Meral Beksac et al.
HAEMATOLOGICA (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
Extramedullary disease in multiple myeloma
Radhika Bansal et al.
BLOOD CANCER JOURNAL (2021)
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome
Meral Beksac et al.
HAEMATOLOGICA (2020)
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Saad Z Usmani et al.
Lancet Haematology (2020)
Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Nico Gagelmann et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Jens Hillengass et al.
LANCET ONCOLOGY (2019)
Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected real-world population
Jiri Minarik et al.
BIOMEDICAL PAPERS-OLOMOUC (2019)
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Nico Gagelmann et al.
HAEMATOLOGICA (2018)
DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma
Hiu Lam Agnes Yuen et al.
LEUKEMIA & LYMPHOMA (2018)
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Nico Gagelmann et al.
HAEMATOLOGICA (2018)
Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma
Arjun Lakshman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
Michele Cavo et al.
LANCET ONCOLOGY (2017)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation
Mathew Weinstock et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
A Comparison of Salvage Infusional Chemotherapy Regimens for Recurrent/Refractory Multiple Myeloma
Patrick T. Griffin et al.
CANCER (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
Inger S. Nijhof et al.
CLINICAL CANCER RESEARCH (2015)
DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
Silvia Park et al.
ANNALS OF HEMATOLOGY (2014)
The lymphoma-like polychemotherapy regimen Dexa-BEAM in advanced and extramedullary multiple myeloma
Leo Rasche et al.
ANNALS OF HEMATOLOGY (2014)
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma
M Lazzarino et al.
BONE MARROW TRANSPLANTATION (2001)
分享论文
